Featured Research

from universities, journals, and other organizations

Implanted Cardioverter Defribillators (ICDs) Extend Lives Of Heart Attack Survivors By An Entire Year: Study

Date:
May 18, 2009
Source:
University of Rochester Medical Center
Summary:
A landmark follow-up study found that heart attack survivors who receive implanted cardioverter defribillators (ICDs) live longer the longer they have them, according to the results of late-breaking clinical trial.

A landmark follow-up study found that heart attack survivors who receive implanted cardioverter defribillators (ICDs) live longer the longer they have them, according to the results of alate-breaking clinical trial presented at the annual Scientific Sessions of the Heart Rhythm Society.

Related Articles


ICDs are devices designed to correct arrhythmias, electrical malfunctions that throw the heart out of rhythm and cause many of the sudden cardiac deaths each year in the United States. Most fatal arrhythmias in the aging are caused by scar tissue left behind by heart attacks that interferes with the heart's electrical system.

The study that first tested the effectiveness of ICDs, the 2002 MADIT II trial (Multicenter Automatic Defibrillator Implantation Trial II), changed medical guidelines nationwide and made thousands of heart attack survivors eligible for ICD therapy. Led by Arthur Moss, M.D., professor of Medicine in the Department of Medicine at the University of Rochester Medical Center, the study found that the devices reduced risk of sudden cardiac death by 31 percent in heart attack survivors. At the same time, the ICD therapy could extend the average patient’s life by about two months over a follow-up period that averaged about 2 years per patient. While that survival benefit was meaningful to patients, some critics argued that it did not make sense for the healthcare system to pay $25,000 for a device that provided a modest extension of life in patients with chronic cardiac disease.

The current study watched the same patients for eight years, and found that over that time, patients with ICDs implant lived an average of more than a year longer, “greatly amplifying” the value of the treatment and arguing that it is dramatically more cost effective as a chronic therapy. Specifically, the new study found that MADIT II patients who had an ICD for eight years had a 37 percent lower chance of death from any cause than those without one, which translates into 1.2 life-years saved.

“These results show that ICDs extend the long-term survival of patients with life-threatening of heart conditions,” said Ilan Goldenberg, M.D., research associate professor within the Heart Research Follow-up Program at the University of Rochester Medical Center, and lead author of the new study. “These results emphasize the life-saving value of ICDs as chronic therapy for high-risk cardiac patients.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Rochester Medical Center. "Implanted Cardioverter Defribillators (ICDs) Extend Lives Of Heart Attack Survivors By An Entire Year: Study." ScienceDaily. ScienceDaily, 18 May 2009. <www.sciencedaily.com/releases/2009/05/090514101941.htm>.
University of Rochester Medical Center. (2009, May 18). Implanted Cardioverter Defribillators (ICDs) Extend Lives Of Heart Attack Survivors By An Entire Year: Study. ScienceDaily. Retrieved November 21, 2014 from www.sciencedaily.com/releases/2009/05/090514101941.htm
University of Rochester Medical Center. "Implanted Cardioverter Defribillators (ICDs) Extend Lives Of Heart Attack Survivors By An Entire Year: Study." ScienceDaily. www.sciencedaily.com/releases/2009/05/090514101941.htm (accessed November 21, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN Says It Will Scale Up Its Ebola Response

UN Says It Will Scale Up Its Ebola Response

AFP (Nov. 20, 2014) UN Resident Coordinator David McLachlan-Karr and WHO representative in the country Daniel Kertesz updated the media on the UN Ebola response on Wednesday. Duration: 00:51 Video provided by AFP
Powered by NewsLook.com
Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Reuters - US Online Video (Nov. 20, 2014) U.S. Congress hears from a victim and company officials as it holds a hearing on the safety of Takata airbags after reports of injuries. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Obesity Costs Almost As Much As War And Terrorism

Obesity Costs Almost As Much As War And Terrorism

Newsy (Nov. 20, 2014) The newest estimate of the cost of obesity is pretty jarring — $2 trillion. But how did researchers get to that number? Video provided by Newsy
Powered by NewsLook.com
Calling All Men: Here's Your Chance to Experience Labor Pains

Calling All Men: Here's Your Chance to Experience Labor Pains

Reuters - Light News Video Online (Nov. 20, 2014) Chinese hospital offers men a chance to experience the pain of child birth via electric shocks. Sharon Reich reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins